NeurologyLive® Friday 5 — February 28, 2025

Welcome to NeurologyLive^®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: Notable Sessions to Eye Amid the 2025 ACTRIMS Forum: Véronique Miron, PhD

The John David Eaton Chair in Multiple Sclerosis at the University of Toronto gave clinical insights on emerging, innovative tracks at the 2025 ACTRIMS Forum and how these sessions align with recent trends in the multiple sclerosis field. [WATCH TIME: 4 minutes]

2: A Shared Perspective on the Newly Approved Nonopioid Alternative for Acute Pain: Jessica Oswald, MD, MPH

The associate professor in pain management and emergency medicine at UC San Diego shared her reaction to the FDA approval of suzetrigine, a selective, nonaddictive alternative to opioids for acute pain management. [WATCH TIME: 4 minutes]

3: Nuances in Thrombectomy Techniques and Anesthesia Use for Stroke: J Mocco, MD, MS

The director of the Cerebrovascular Center at Mount Sinai discussed how results from the ESCAPE-MeVO trial highlight the impact of anesthesia rates, thrombectomy techniques, and the need for rigorous clinical trials to minimize bias. [WATCH TIME: 3 minutes]

4: NeuroVoices: John Brandsema, MD, on Updates in Gene Therapy at MDA 2025

The pediatric neurologist provided a clinical overview of the advances and roadblocks of gene therapy in neuromuscular disorders, which will be highlighted at the 2025 MDA Clinical & Scientific Conference.

5: Steps in Translating Genetic Discoveries Into Effective Treatments for ALS: Matthew B. Harms, MD

The associate professor of neurology at Columbia University provided commentary on the rapid advancements in translating genetic research into ALS treatments and the challenges that remain. [WATCH TIME: 5 minutes]